# Hanza Q1: Softer than Expected

Hanza Research Note 2024-05-07 © 08:05


Redeye sees a softer Q1 report from Hanza than expected. While the like-for-like numbers were somewhat softer than expected, Orbit One seems to be the main driver behind the soft quarter. However, management expects a rebound in volumes already in the autumn of 2024. We will likely reduce our forecasts and Base Case.



#### Fredrik Nilsson

- Sales was 6% short of our expectations and amounted to SEK1253m (1065). The organic growth was -6% y/y. The softer macroeconomic environment resulted in lower demand from customers in some areas.
- EBITA (adjusted for restructuring and a write-down of the Orbit One earn-out) was SEK67m (88), corresponding to an EBITA margin of 5.3% (8.3). Our forecast was SEK96m and 7.2%.
- Main Markets beat our sales forecasts by 5%, while EBITA came in 11% short. We believe
  the EBITA contribution from Orbit One was lower than we anticipated, as management
  states that the EBITA contribution in Q1 was limited. Thus, the like-for-like EBITA
  development was rather solid at 8.2% vs 8.8% Q1 2023 (excluding subsidiaries). Organic
  growth was 1%.
- Other Markets came in below in terms of both sales and EBITA. Organic growth was -14%, and the EBITA margin fell to 3.3% overall and 4.9% (6.4) like-for-like. Our forecast was 6.1%.
- While Hanza saw reductions in order intake at the beginning of 2024, no customers were lost, and Hanza expects increases in volumes in the autumn of 2024. At the same time, some customers continue to grow.
- Although the overall like-for-like numbers were somewhat below our expectations, Orbit One seems to be experiencing a tough market, like many EMS-focused listed companies and was the main driver behind the soft Q1.
- We will likely reduce our forecasts and Base Case.

Estmates vs. Actuals					
Sales	Q1E 2024	Q1A 2024	Diff	Q1A 2023	Q4A 2023
Net sales	1334	1253	-6%	1065	1056
Y/Y Growth (%)	33%	18%		29%	5%
Main Markets	735	770	5%	594	605
Y/Y Growth (%)	21%	30%		23%	6%
EBITA (MM)	61	54	-11%	58	63
EBITA margin	8.3%	7.0%		10%	10%
Other Markets	599	480	-20%	468	447
Y/Y Growth (%)	34%	3%		37%	2%
EBITA (OM)	37	16	-56%	30	29
EBITA margin	6.1%	3.3%		6%	6%
Earning					
EBITA	96	67	-30%	88	76
EBITA Margin (%)	7.2%	5.3%		8.3%	7.2%
EBIT	92	61	-34%	84	71
EBIT Margin (%)	6.9%	4.9%		7.9%	6.7%
Diluted EPS	1.32	0.77	-42%	1.48	1.09
Source: Hanza & Redeye Research   Segn	nent EBITA concerns ad	justed numbers			



### KEY STATS

Market Cap	2.5 BSEK
Entprs. Value (EV)	3.0 BSEK
Net Debt (2024e)	532.4 MSEK
30 Day Avg Vol	98 K
Shares Outstanding	43.7M
Price / Earnings	10.1x
PEG	1.1x
Dividend Yield	2.4%
<b>Data from</b> 2024-05	5-07 © 08:14

## IMPORTANT INFORMATION

All information regarding limitation of liability and potential conflicts of interest can be found at the end of the report.

Redeye, Mäster Samuelsgatan 42, 10tr, Box 7141, 103 87 Stockholm. Tel. +46 8-545 013

E-post: info@redeye.se

## **Disclaimer**

## Important information

Redeye AB ("Redeye" or "the Company") is a specialist financial advisory boutique that focuses on small and mid-cap growth companies in the Nordic region. We focus on the technology and life science sectors. We provide services within Corporate Broking, Corporate Finance, equity research and investor relations. Our strengths are our award-winning research department, experienced advisers, a unique investor network, and the powerful distribution channel redeye.se. Redeye was founded in 1999 and since 2007 has been subject to the supervision of the Swedish Financial Supervisory Authority.

Redeye is licensed to; receive and transmit orders in financial instruments, provide investment advice to clients regarding financial instruments, prepare and disseminate financial analyses/recommendations for trading in financial instruments, execute orders in financial instruments on behalf of clients, place financial instruments without position taking, provide corporate advice and services within mergers and acquisition, provide services in conjunction with the provision of guarantees regarding financial instruments and to operate as a Certified Advisory business (ancillary authorization).

## **Limitation of liability**

This document was prepared for information purposes for general distribution and is not intended to be advisory. The information contained in this analysis is based on sources deemed reliable by Redeye. However, Redeye cannot guarantee the accuracy of the information. The forward-looking information in the analysis is based on subjective assessments about the future, which constitutes a factor of uncertainty. Redeye cannot guarantee that forecasts and forward-looking statements will materialize. Investors shall conduct all investment decisions independently. This analysis is intended to be one of a number of tools that can be used in making an investment decision. All investors are therefore encouraged to supplement this information with additional relevant data and to consult a financial advisor prior to an investment decision. Accordingly, Redeye accepts no liability for any loss or damage resulting from the use of this analysis.

#### Potential conflict of interest

Redeye's research department is regulated by operational and administrative rules established to avoid conflicts of interest and to ensure the objectivity and independence of its analysts. The following applies:

- For companies that are the subject of Redeye's research analysis, the applicable rules include those established by the Swedish Financial Supervisory Authority pertaining to investment recommendations and the handling of conflicts of interest. Furthermore, Redeye employees are not allowed to trade in financial instruments of the company in question, from the date Redeye publishes its analysis plus one trading day after this date.
- An analyst may not engage in corporate finance transactions without the express approval of management and may not receive any remuneration directly linked to such transactions.
- Redeye may carry out an analysis upon commission or in exchange for payment from the company that is the
  subject of the analysis, or from an underwriting institution in conjunction with a merger and acquisition (M&A) deal,
  new share issue or a public listing. Readers of these reports should assume that Redeye may have received or will
  receive remuneration from the company/companies cited in the report for the performance of financial advisory
  services. Such remuneration is of a predetermined amount and is not dependent on the content of the analysis.

## Redeye's research coverage

Redeye's research analyses consist of case-based analyses, which imply that the frequency of the analytical reports may vary over time. Unless otherwise expressly stated in the report, the analysis is updated when considered necessary by the research department, for example in the event of significant changes in market conditions or events related to the issuer/the financial instrument.

#### **Recommendation structure**

Redeye does not issue any investment recommendations for fundamental analysis. However, Redeye has developed a proprietary analysis and rating model, Redeye Rating, in which each company is analyzed and evaluated. This analysis aims to provide an independent assessment of the company in question, its opportunities, risks, etc. The purpose is to provide an objective and professional set of data for owners and investors to use in their decision-making.

## **Duplication and distribution**

This document may not be duplicated, reproduced or copied for purposes other than personal use. The document may not be distributed to physical or legal entities that are citizens of or domiciled in any country in which such distribution is prohibited according to applicable laws or other regulations.

Copyright Redeye AB.